Skye Bioscience (SKYE) Gross Margin (2013 - 2014)
Skye Bioscience (SKYE) posted quarterly Gross Margin of 77.3% for Q2 2014, down 287.0% year-over-year from 41.33% in Q2 2013, and down 3.02% quarter-over-quarter from 79.7% in Q4 2013.
Skye Bioscience (SKYE) Gross Margin (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported Gross Margin for 2 consecutive years, with 77.3% the latest figure, recorded in Q2 2014.
- In Q2 2014, Gross Margin fell 287.0% year-over-year to 77.3%; the TTM figure through Apr 2014 stood at 78.9% (changed N/A YoY), while the FY2013 annual figure was 80.2%, down 1736.0% from the prior year.
- Gross Margin fell to 77.3% in Q2 2014 per SKYE's latest filing, from 79.7% in the prior quarter.
- Across five years, Gross Margin topped out at 82.81% in Q1 2013 and bottomed at 77.3% in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2014 | 77.30% |
| Oct 31, 2013 | 79.70% |
| Jul 31, 2013 | 79.07% |
| Apr 30, 2013 | 80.17% |
| Jan 31, 2013 | 82.81% |